You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

ID: Guideline Endorsement C50-CIDAP-3 mar 2025
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
S. Das, J. Greenspoon, K.J. Jerzak, T. Nguyen, T.L. Ng, R. Ramos, F. Ynoe de Moraes, D. Bhatti, the Brain Radiation Necrosis Guideline Endorsement Expert Panel

Guideline Objective

The objective of this guideline is to provide recommendations on the management of symptomatic brain radiation necrosis after stereotactic radiosurgery. The recommendations are based on the 2023 International Stereotactic Radiosurgery Society’s Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and International Stereotactic Radiosurgery Society Recommendations.

Patient Population

Patients receiving stereotactic radiosurgery (SRS)/stereotactic radiotherapy (SRT) for brain metastases and presenting with symptomatic brain radiation necrosis after stereotactic radiosurgery.

Intended Guideline Users

The guideline document will support providers, including neuro-oncologists, neurosurgeons, radiation oncologists, medical oncologists, pathologists, radiologists etc., in the management of patients presenting with symptomatic brain radiation necrosis after stereotactic radiosurgery.

Research Questions

Endorsement, no research questions.

pdf download Full Report (PDF) (1.01 Mo)